1
|
Hussain MS, Gupta G, Mishra R, Patel N, Gupta S, Alzarea SI, Kazmi I, Kumbhar P, Disouza J, Dureja H, Kukreti N, Singh SK, Dua K. Unlocking the secrets: Volatile Organic Compounds (VOCs) and their devastating effects on lung cancer. Pathol Res Pract 2024; 255:155157. [PMID: 38320440 DOI: 10.1016/j.prp.2024.155157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Revised: 01/15/2024] [Accepted: 01/18/2024] [Indexed: 02/08/2024]
Abstract
Lung cancer (LCs) is still a serious health problem globally, with many incidences attributed to environmental triggers such as Volatile Organic Compounds (VOCs). VOCs are a broad class of compounds that can be released via various sources, including industrial operations, automobile emissions, and indoor air pollution. VOC exposure has been linked to an elevated risk of lung cancer via multiple routes. These chemicals can be chemically converted into hazardous intermediate molecules, resulting in DNA damage and genetic alterations. VOCs can also cause oxidative stress, inflammation, and a breakdown in the cellular protective antioxidant framework, all of which contribute to the growth of lung cancer. Moreover, VOCs have been reported to alter critical biological reactions such as cell growth, apoptosis, and angiogenesis, leading to tumor development and metastasis. Epidemiological investigations have found a link between certain VOCs and a higher probability of LCs. Benzene, formaldehyde, and polycyclic aromatic hydrocarbons (PAHs) are some of the most well-researched VOCs, with comprehensive data confirming their cancer-causing potential. Nevertheless, the possible health concerns linked with many more VOCs and their combined use remain unknown, necessitating further research. Identifying the toxicological consequences of VOCs in LCs is critical for establishing focused preventative tactics and therapeutic strategies. Better legislation and monitoring mechanisms can limit VOC contamination in occupational and environmental contexts, possibly reducing the prevalence of LCs. Developing VOC exposure indicators and analyzing their associations with genetic susceptibility characteristics may also aid in early identification and targeted therapies.
Collapse
Affiliation(s)
- Md Sadique Hussain
- School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan 302017, India
| | - Gaurav Gupta
- Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, India; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, 346, United Arab Emirates; School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India
| | - Riya Mishra
- School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India
| | - Neeraj Patel
- School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India
| | - Saurabh Gupta
- Chameli Devi Institute of Pharmacy, Department of Pharmacology, Khandwa Road, Village Umrikheda, Near Toll booth, Indore, Madhya Pradesh 452020, India
| | - Sami I Alzarea
- Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, 72341, Al-Jouf, Saudi Arabia
| | - Imran Kazmi
- Department of Biochemistry, Faculty of Science, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
| | - Popat Kumbhar
- Tatyasaheb Kore College of Pharmacy, Warananagar, Tal: Panhala Dist: Kolhapur, Maharashtra 416113, India
| | - John Disouza
- Tatyasaheb Kore College of Pharmacy, Warananagar, Tal: Panhala Dist: Kolhapur, Maharashtra 416113, India
| | - Harish Dureja
- Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, India
| | - Neelima Kukreti
- School of Pharmacy, Graphic Era Hill University, Dehradun 248007, India
| | - Sachin Kumar Singh
- School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia
| | - Kamal Dua
- Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia.
| |
Collapse
|
2
|
Smith TJ, Bois FY, Lin YS, Brochot C, Micallef S, Kim D, Kelsey KT. Quantifying heterogeneity in exposure-risk relationships using exhaled breath biomarkers for 1,3-butadiene exposures. J Breath Res 2008; 2:037018. [PMID: 21386179 DOI: 10.1088/1752-7155/2/3/037018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The health effects of human exposure to 1,3-butadiene (BD) have been extensively studied using both epidemiological and animal toxicology approaches. However, various data and knowledge gaps remain, one of which is an understanding of the human heterogeneity in BD dosimetry. The objective of our study was to better understand the role of individual variability in delivered tissue dose. We designed a study of laboratory exposures of a relatively large group of healthy human subjects. Subjects were then exposed to 2.0 ppm BD through a face mask for 20 min, followed by 40 min of breathing clean air. Exhaled breath concentrations of BD were measured at ten time points during and after exposure, and a three-compartment physiologically based pharmacokinetic (PBPK) model was used to quantify the kinetic behavior of BD. We implemented a Markov chain Monte Carlo procedure to fit the model to the experimental data, and used global sensitivity analysis techniques to examine the sensitivity of exhaled breath concentrations to PBPK model parameters. Uptake during exposure was strongly influenced by rebreathing of exhaled BD during exposure; inclusion of rebreathing in the model simulations resulted in a 21% increase in the amount of BD retained in the body. We found that uptake ranged from 38% to 77% across individuals. We measured considerable intra-individual variability from 11 subjects who underwent the testing twice. Most of this variation stemmed from phase I metabolism of BD, which varied by as much as a factor of 2.6 within individuals. Overall, we have sought to quantify the sources of inter- and intra-individual variabilities in the pharmacokinetic behavior of BD. The results of our research may impact the current framework for biomarker and pharmacokinetic studies by improving our understanding of the sources of heterogeneity in response to chemical exposures.
Collapse
Affiliation(s)
- Thomas J Smith
- Department of Environmental Health, School of Public Health, Harvard University, 665 Huntington Avenue, Boston, MA 02115, USA
| | | | | | | | | | | | | |
Collapse
|
4
|
Abstract
Published epidemiologic studies of butadiene workers, individually and in aggregate, find rates similar to expected for essentially all forms of cancer, with the possible exception of lymphohematopoietic cancers. Reviewers of the literature have disagreed about whether butadiene is a cause of human lymphohematopoietic cancers. This article reviews the available butadiene epidemiologic studies and focuses on the bases for disagreement among reviewers. The disagreement seems to be due to different conventions in applying, explicitly or implicitly, Hill's causal criteria, fostered, in part, by deficiencies in the available epidemiologic studies. Many of these deficiencies will be remedied by updated studies presented at this Symposium or are remediable by other analyses of the existing data.
Collapse
|
5
|
Melnick RL, Shackelford CC, Huff J. Carcinogenicity of 1,3-butadiene. ENVIRONMENTAL HEALTH PERSPECTIVES 1993; 100:227-36. [PMID: 8354171 PMCID: PMC1519572 DOI: 10.1289/ehp.93100227] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
1,3-Butadiene, a high-production volume chemical used largely in the manufacture of synthetic rubber, is a multiple organ carcinogen in rats and mice. In inhalation studies conducted in mice by the National Toxicology Program, high rates of early lethal lymphomas occurring at exposure levels of 625 ppm or higher reduced the development and expression of later developing tumors at other sites. Use of survival-adjusted tumor rates to account for competing risk factors provided a clearer indication of the dose responses for 1,3-butadiene-induced neoplasms. An increase in lung tumors in female mice was observed at exposure concentrations as low as 6.25 ppm, the lowest concentration ever used in a long-term carcinogenicity study of this gas. Human exposures to 1,3-butadiene by workers employed at facilities that produce this chemical and at facilities that produce styrene-butadiene rubber have been measured at levels higher than those that cause cancer in animals. Furthermore, epidemiology studies have consistently revealed associations between occupational exposure to 1,3-butadiene and excess mortality due to lymphatic and hematopoietic cancers. In response to the carcinogenicity findings for 1,3-butadiene in animals and in humans, the Occupational Safety and Health Administration has proposed lowering the occupational exposure standard for this chemical from 1000 ppm to 2 ppm. Future work is needed to understand the mechanisms of tumor induction by 1,3-butadiene; however, the pursuit of this research should not delay the reduction of human exposure to this chemical.
Collapse
Affiliation(s)
- R L Melnick
- National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709
| | | | | |
Collapse
|
6
|
Acquavella JF. Future directions in epidemiologic studies of 1,3-butadiene-exposed workers. ENVIRONMENTAL HEALTH PERSPECTIVES 1990; 86:129-134. [PMID: 2401253 PMCID: PMC1567723 DOI: 10.1289/ehp.9086129] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
To date, epidemiologic research on 1,3-butadiene has consisted of cohort mortality studies of workers in the styrene-butadiene rubber (SBR) and butadiene monomer industries. These studies have been extremely useful both in defining the focus on human health effects to the lymphopoietic cancers and in providing a perspective on which to evaluate the available animal models for human risk assessment. The next step for epidemiologic research will involve a lymphopoietic cancer case control approach to enable a more precise assessment of whether there is a relationship between 1,3-butadiene exposure and lymphopoietic cancer. In addition, periodic mortality updates of the 1,3-butadiene-exposed worker cohorts will be important to monitor trends in lymphopoietic cancer rates and to ensure that other cancers with long latency do not begin to show elevated rates. This paper describes an industry-sponsored program of case-control and cohort mortality update studies along with the critical elements in research design and analysis for each study. Epidemiological studies will play an important role in testing hypotheses developed from toxicological studies about potential biological mechanisms of 1,3-butadiene carcinogenesis in humans.
Collapse
|